Compare · NNNN vs TNFA
NNNN vs TNFA
Side-by-side comparison of Anbio Biotechnology (NNNN) and TNF Pharmaceuticals Inc. (TNFA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and TNFA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN carries a market cap of $1.53B.
- Over the past year, NNNN is down 72.9% and TNFA is down 50.9% - TNFA leads by 22.0 points.
PerformanceNNNN-26.27%TNFA-50.90%
2026-06-10+0.00%2026-08-03
- Company
- Anbio Biotechnology
- TNF Pharmaceuticals Inc.
- Price
- $11.65+19.49%
- $5.17+47.50%
- Market cap
- $1.53B
- -
- 1M return
- -7.69%
- -24.75%
- 1Y return
- -72.88%
- -50.90%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest NNNN
- SEC Form F-3ASR filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Zhang Michael W.C
- SEC Form 3 filed by new insider Hsu David H
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
Latest TNFA
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
- TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing
- TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form D filed by TNF Pharmaceuticals Inc.
- TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits